NCT01207492 2026-02-20
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
14 trialsNCT04205903 2025-06-29
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02269267 2023-03-03
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Medical College of Wisconsin
Phase 2 Completed
NCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02353728 2022-03-25
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Weill Medical College of Cornell University
Phase 2 Completed
NCT01140568 2020-05-05
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
University of California, San Diego
Phase 2 Completed
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00129740 2019-09-24
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00788775 2018-11-15
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02709083 2018-11-02
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
Phase 2 Terminated
NCT00702403 2017-08-10
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01275586 2017-04-12
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase EARLY_PHASE1 Completed
NCT01089595 2017-03-15
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Fox Chase Cancer Center
Phase 2 Terminated
NCT00782834 2013-04-22
07060
Fox Chase Cancer Center
Phase 2 Terminated